Fenbendazole is an animal anthelmintic with an established track record of human safety and effectiveness. It has been shown to be effective in high doses (>1.0 g per day) against the parasites Ascaris, hookworm and Trichuris. It is also well tolerated in humans at doses of up to 1.5 g per day.
In addition to its moderate microtubule depolymerizing effect, fenbendazole has been found to have antitumor effects in in vitro and in vivo experiments. For example, in a study of A549 lung cancer cells with KRAS mutation, Dogra et al found that 1 mg/mouse of fenbendazole, a drug commonly used to treat rodent pinworm infections, induced a significant shrinkage of tumors when administered orally to mice.
Additionally, a recent study showed that the treatment of human colon cancer organoids with fenbendazole significantly inhibited tumor growth. The researchers theorized that fenbendazole may work by blocking the cell cycle, preventing the synthesis of proteins required for progression through anaphase.
The authors of this article conducted focus group interviews with 21 cancer patients who had self-administered fenbendazole to treat their non-small-cell lung cancer. The interviewees were asked to answer questions about the process through which they acquired general cancer information and socially issued cancer information daily. Their answers revealed that the majority of their information about fenbendazole came from acquaintances and TV, followed by YouTube and the Internet. In most cases, patients were already familiar with the claim that fenbendazole could shrink their tumors and actively sought out Joe Tippens’ videos on YouTube to confirm the information they had received through other channels. fenbendazole for cancer